Difference between revisions of "WSI22-127-Case-2"

From MGH Learn Pathology
(Added status template)
 
(One intermediate revision by one other user not shown)
Line 44: Line 44:
 
|subject=Z0FBQUFBQmpJNXVCX01xR0JjbGNySTdUbHRUbTF5clk4bEd4Qnp4NEtVZnQtSzhIdlhGZ3haWkt1SHUzOTJCRGo1S1lkdE1MMzQ5RC1lV1hOSGRRQXc1Ung0QXI2ejZ6Vmc9PQ
 
|subject=Z0FBQUFBQmpJNXVCX01xR0JjbGNySTdUbHRUbTF5clk4bEd4Qnp4NEtVZnQtSzhIdlhGZ3haWkt1SHUzOTJCRGo1S1lkdE1MMzQ5RC1lV1hOSGRRQXc1Ung0QXI2ejZ6Vmc9PQ
 
|reasonCode=H&E
 
|reasonCode=H&E
|view=hide
+
|view=show
 
|modality=mrxs
 
|modality=mrxs
 +
}}
 +
{{status
 +
|status=active
 +
|requester=Af400
 +
|authoredOn=September 15, 2022 09:34:48 PM
 
}}
 
}}

Latest revision as of 14:30, December 9, 2024

WSI22-127-Case-2
30s female with thyroid mass and enlarged bilateral lymph nodes.
Papillary thyroid carcinoma, diffuse sclerosing variant. Follow-up molecular: CCDC6(e1)::RET(e12) fusion.
October 26, 2022 1:15:00 AM